Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAISHAN-303: YL201 versus investigator's choice chemotherapy in previously treated advanced or metastatic esophageal squamous cell carcinoma
CTR20261009Phase 3Active
- Sponsor
- MediLink Therapeutics
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of YL201 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by MediLink Therapeutics. Started Apr 2026; status: active.
02
Drugs
YL201
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20261009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261009.